Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed, a healthcare investment firm.

The investment will be used by Cellipont to fully finance the previously announced state-of-the-art commercial facility for cell therapies and gene-modified cell therapies in The Woodlands, TX.

The 76,000-square-foot facility will feature significant capabilities including process and analytical development (PD/AD) and manufacturing services for CAR-T, IPSC, MSC and other types of cell therapies. OrbiMed’s support will enable clients to take advantage of cutting-edge cleanrooms, promising technological innovations, and a team with deep scientific expertise in a best-in-class facility.